ICH Q9 is the International Council for Harmonisation's guideline on quality risk management for drug substances and drug products across the product lifecycle. It sets out a process for assessing, controlling, communicating and reviewing risks to quality, with the effort and formality in proportion to the risk. Inspectors read risk-based decisions against it. There is no Q9 certificate.
The current version is Q9(R1), which reached ICH Step 4 in January 2023. The revision kept the process and the annex of tools and added guidance on formality, on managing subjectivity, on risk-based decision making and on risks to product availability. The FDA published it as guidance in May 2023, and in the EU it sits in Eudralex Volume 4 Part III.



